Symposium: les douleurs thoraciques alarmantes. Les douleurs thoraciques alarmantes d'origine oesophagienne.

Journal Articleinfo:eu-repo/semantics/publishe

The contribution of the aminopyrine-breath-test in metastatic liver disease [2]

SCOPUS: le.jinfo:eu-repo/semantics/publishe

Paradoxical contraction of pelvic floor muscles: Clinical significance

Paradoxical contraction of pelvic floor muscles during defecation straining has been said to be a cause of constipation and difficulty in passing feces. Nevertheless, controversies about its clinical significance still remained. Twenty patients with constipation and electromyographic evidence of paradoxical contraction of both puborectalis and external anal sphincter were investigated. An anorectal manometry performed in 17 confirmed the paradoxical contraction in 13 (76%). Electromyography revealed neurogenic signs in 11. Defecography demonstrated the paradoxical contraction in 6 only, but, together with barium enema and colon transit time, showed associated anorectal disorders in 9 patients. Twenty control patients were also studied. None had difficulty defecating. Nevertheless, 8 of them (40%) had paradoxical contraction. These observations suggest that paradoxical contraction of pelvic floor muscles may be asymptomatic and that another cause of emptying difficulties has always to be looked for.SCOPUS: cp.jinfo:eu-repo/semantics/publishe

Anorectal incontinence in myotonic dystrophy: A myopathic involvement of pelvic floor muscles [3]

SCOPUS: le.jFLWNAinfo:eu-repo/semantics/publishe

Non-surgical management of achalasia

SCOPUS: cp.jinfo:eu-repo/semantics/publishe

A phase I trial of a new antiemetic drug-clebopnde malate-in cisplatin-treated patients

Clebopride, a new benzamide derivative, has, in common with the other members of this group, antidopaminergic activity. In animals, its therapeutic ratio is superior to that of metoclopramide at doses free of side effects associated with hyperprolactinemia and extrapyramidal symptoms. The present study was designed to define the maximum tolerated dose (MTD) in patients with advanced histologically-proven cancer, treated with cisplatin at a dose of greater than 50 mg/m2. Most of them were pretreated and refractory to standard antiemetics. Clebopride was started at a dosage of 0.10 mg/kg in a group of 6 patients and escalated by 0.2 mg at each dose level. A total of 30 patients were included. Side effects include somnolence, diarrhea and extrapyramidal-like symptoms. The latter occurred at almost all dose levels in 14% of the cycles and limited continuation of the study. Activity in this group of patients was encouraging but, considering the rate of extrapyramidal symptoms, further dose escalation is not indicated and activity at lower, nontoxic levels should be investigated.Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tinfo:eu-repo/semantics/publishe

Lack of risk factors for symptomatic postoperative recurrence of Crohn's disease

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

CRYPTOSPORIDIUM IN PATIENT WITH ACQUIRED IMMUNODEFICIENCY SYNDROME

SCOPUS: le.jinfo:eu-repo/semantics/publishe

Management of dysphagia in suspected esophageal motor disorders

SCOPUS: ar.jinfo:eu-repo/semantics/publishe